Abstract: Onset-hastened and enhanced antipyretic response is elicited in a human mammal in need of such treatment, i.e., a human mammal suffering from elevated body temperature (fever), by administering thereto a unit dosage onset-hastening/enhancing antipyretically effective amount of the S(+) ketoprofen enantiomer, said enantiomer being substantially free of its R(-) ketoprofen antipode.

Abstract: A storage-stable preparation, containing the ingredients of freshly recovered wheat vinasse, is prepared after optional removal of husks by grinding to colloidal size and drying under mild conditions, whereafter to the product thus obtained optionally are added fluxing agents, wetting agents, aroma ingredients and further powdery or oily vegetable extracts.

Abstract: A pharamaceutical composition in solid unit dosage form comprising (a) a therapeutically effective amount of a piperidinoalkanol compound, or a pharmaceutically acceptable salt thereof, (b) pharmaceutically acceptable nonionic or cationic surfactant in an amount of from about 0.1% to about 6% by weight of the composition, and (c) pharmaceutically acceptable carbonate salt in an amount of from about 2% to about 50% by weight of the composition.

Abstract: Formulae, means, and methods for the sublingual ingestion of natural Progesterone comprising milling and blending natural Progesterone such that it can be absorbed by the sublingual mucosae of a patient and applying it to said sublingual mucosae in a form which permits such absorption.

Abstract: Sustained and enhanced analgesic response is elicited in a mammalian organism in need of such treatment, i.e., a mammal suffering pain, by administering thereto a unit dosage sustainedly enhancing, analgesically effective amount of the free acid S(+) flurbiprofen enantiomer, said enantiomer being substantially free of its R(-) flurbiprofen antipode.

Abstract: A drug delivery system comprising a core material comprising a drug, and a hydrophobic matrix coating the core. The coating delays hydration of the drug and masks the taste of the drug. The coating comprises an emulsifier, an edible fatty acid or wax and a glyceride. The delivery system can be incorporated into various food products, pharmaceutical preparations and proprietary products.

Abstract: Disclosed herein is an immunoregulator comprising a derivative of estradiol represented by the formula (I), which immunoregulator has a small influence to the non-specific immunoreactions in general and gives a specific influence to the immunoreactions against an isoantibody.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkylenglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lenghts of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant maerial selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coatd with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and p1 (b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons of less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: A chewable delivery system for actives comprising:(a) an active pre-coated with at least one material selected from the group consisting of lecithin, polyoxyalkylenes having chain lengths of about 4 carbons or less, glycerides having a melting point of 100.degree. C. or less, polyalkyleneglycols having a molecular weight of 3,700 or less, synthetic and natural waxes and mixtures thereof; and(b) a confectionery matrix comprising a binder system comprising gelatin and a humectant material selected from the group consisting of glycerin and its lower alkyl (C.sub.2-7) ester derivatives; a sweetener; and about 1% to about 30% by weight water.

Abstract: Crystalline complexes of steroid hormones with gamma-cyclodextrin are prepared by mixing the components together. Tablets can be formed from the complexes, which can be administered by contact with the mucosa to provide effective transfer of the hormones into the systemic circulation, gradually eliminating the hormones therefrom.

Abstract: Onset-hastened and enhanced analgesic response is elicited in a mammalian organism in need of such treatment, i.e., a mammal suffering pain, by administering thereto a unit dosage onset-hastening/enhancing analgesically effective amount of the S(+) ketoprofen enantiomer, said enantiomer being substantially free of its R(-) ketoprofen antipode.

Abstract: The present invention provides a medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant.The present invention also provides a process for the production of a clodronate-containing medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant, wherein the dry components are mixed, moist granulated with an aqueous binding agent and the granulate obtained subsequently dried, a lubricant being additionally admixed with the final granulate in an amount of from 1 to 5% and the mixture thus obtained pressed into tablets or filled into capsules which have a rate of dissolving of >90% after 30 minutes.

Abstract: Onset-hastened and enhanced analgesic response is elicited in a mammalian organism in need of such treatment, i.e., a mammal suffering pain, by administering thereto a unit dosage onset-hastening/enhancing analgesically effective amount of the S(+) ibuprofen enantiomer, said enantiomer being substantially free of its R(-) ibuprofen antipode.

Abstract: 5-Amino or substituted amino 1,2,3-triazoles are disclosed as a new class of antiproliferative agents useful in the treating and managing of psoriasis, inflammatory bowel syndrome, cutaneous leishmanilisis and certain types of cancer.

Abstract: The subject invention relates to a process for preparing lubricated water-soluble vitamin powders. The water-soluble vitamin powders are lubricated by combining them with a lubricant at a temperature sufficient to melt the lubricant. The powders are directly compressible into tablets and are resistant to demixing.

Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.

Abstract: An orally administrable composition and method for reducing serum cholesterol levels are disclosed. A pharmaceutical composition comprising a gel-forming fiber such as, for example, guar gum, pysllium seed, pectin, glucomannon, oat and barley and a mineral salt such as for example, calcium carbonate, magnesium carbonate and potassium carbonate is administered to humans to reduce serum cholesterol levels.

Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.

Abstract: There is disclosed a nicotine containing lozenge prepared from a mixture of inert filler material, a binder and either pure nicotine or a nicotine containing substance by a technique not involving any application of heat. Cold compression in a conventional tablet making machine is preferred.

Abstract: A method for producing a stable pharmaceutical preparation containing nicorandil as an active ingredient is disclosed. The stable preparation is produced by mixing nicorandil, one or more finely comminuted sugars, and/or one or more powdery organic acids.Nicorandil which is useful as a curative for various types of angina pectoris is not stable against the compressive pressure exerted by punching operations in tabelt making or against moisture.The preparation of nicorandil manufactured by this invention is very stable and useful in clinical applications.

Abstract: Novel tablets comprising (a) 80 to 98% by weight of a mixture of trimethoprim and/or an acid addition salt thereof and a sulfonamide and/or a salt thereof in a weight ratio of 1:20 to 20:1 and (b) a pharmaceutically acceptable synthetic ion exchange resin having improved disintegration times and other properties and a process for their preparation.

Abstract: Biphenylylpropionic acid derivatives of the formula: ##STR1## wherein R is an alkylcarbonyloxyalkyl group or an alkenylcarbonyloxyalkyl group having the formula: ##STR2## wherein R.sup.1 is a lower alkyl group having 1 to 5 carbon atoms and R.sup.2 is an alkyl group having 1 to 15 carbon atoms or an alkenyl group having 2 to 8 carbon atoms, or a lactone having the formula: ##STR3## wherein R.sup.3 and R.sup.4 are hydrogen atom or a lower alkyl group having 1 to 2 carbon atoms, and n is an integer of 1 or 2. The compounds have excellent anti-inflammatory, analgesic and antipyretic activities. Moreover, the compounds have no irritation, rapid and long-acting, and high safety margin.

Abstract: An improved method for preparing tablets useful in diagnostic and therapeutic applications, utilizing trehalose as an excipient and stabilizer, is provided.

Abstract: A medicament adsorbate of analgesics and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein an analgesic. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: New solid galenical form for oral administration, consisting of a mixture of one or more active products and two or more excipients which can be liquefied at a temperature compatible with the active product or products, and which are solid at ambient temperature.

Abstract: A medicament adsorbate of decongestants and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein a decongestant. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: A medicament adsorbate of antiasthmatics and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein an antiasthmatic. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: This invention is concerned with a composition for solid pharmaceutical preparations of active vitamins D.sub.3, having the remarkably improved stability of active vitamins D.sub.3, and an extremely advantageous process for the preparation thereof from the industrial viewpoint. The composition of this invention is a composition for solid pharmaceutical preparations of active vitamins D.sub.3 prepared by forming an outer layer comprising active vitamins D.sub.3 and an excipient, which is readily soluble in an organic solvent, around an inner layer comprising an excipient which is slightly soluble in an organic solvent.

Abstract: A pharmaceutical composition comprising a freely flowable powder, the powder comprising a porous, high absorption silica or silicate having absorbed therein at least 10% by volume of a liquid, pharmaceutically active composition, based on the weight of powder plus liquid, provided that when the liquid pharmaceutically active composition is a corticoid solution the silica or silicate has a mean particle size of at least 10 .mu.m in diameter.

Abstract: Novel tablets comprising (a) 80 to 98% by weight of a mixture of trimethoprim and/or an acid addition salt thereof and a sulfonamide and/or a salt thereof in a weight ratio of 1:20 to 20:1 and (b) a pharmaceutically acceptable synthetic ion exchange resin having improved disintegration times and other properties and a process for their preparation.

Abstract: Disclosed are water soluble effervescent antacid, analgesic powder and tablet formulations which in a preferred embodiment are sodium, sucrose and aspirin free. The formulation is administered through the ingestion of an aqueous solution of the powder or tablet.The powder and tablet formulations of this invention preferably comprise a therapeutically effective amount of acetaminophen as the analgesic and an effective amount of agglomerated particles of an antacid and a food grade acid which will react in an aqueous solution to produce visible gaseous effervescence.The formulations of this invention preferably also comprise flavorants, which improve the taste and lubricants and hardening agents which aid in tableting the formulation.

Abstract: The invention relates to a sustained release tablet which comprises easily disintegrable granules containing(a) a drug,(b) a disintegrating agent selected from the group consisting of starch derivatives, gums, cellulose derivatives and ion-exchange resins, and(c) a water soluble polymer selected from the group consisting of cellulose derivatives, synthetic water soluble polymers and polysaccharides, the surfaces of which granules are treated solely with a wax selected from the group consisting of plant or animal wax, hydrogenated oils and paraffin.

Abstract: Soft gelatin capsules containing a solution of from 15 to 30 parts by weight of ibuprofen in from 70 to 85 parts by weight of polyoxyethylene-polyoxypropylene polymer or in a mixture of from 30 to 76 parts by weight of polyalkylene glycol and from 7 to 40 parts by weight of a surfactant have a very rapid and high bio-availability of the active ingredient. The active ingredient is not re-precipitated therefrom by aqueous media such as artificial gastric juice.

Abstract: Effervescent compositions in the form of tablets or powders comprising a therapeutic agent, a granulating agent, a microparticulate effervescent component and an effervescent system which dissolve rapidly in water to yield an effervescent solution containing a completely dissolved therapeutic agent and a process for their preparation.

Abstract: This application discloses tablets having a harder outer shell which inhibits penetration of liquid into the interior of the tablet, and a softer interior which quickly liquifies when the tablet and shell are broken into pieces and contacted by the liquid. The tablet has particular utility as a chewable tablet which resists absorption of moisture but which quickly liquifies and melts in the mouth within seconds after mastication, even if the tablet contains considerable amounts of active ingredients that do not dissolve well or at all in the mouth. Also disclosed are agglomerates from which the tablets are directly compressed, and processes for making the agglomerates and tablets. The tablets contain increased quantities of active ingredients of up to about 75% by weight.

Abstract: A gelatin capsule dosage form containing triamterene, 2,4,7-triamino-6-phenylpteridine, which results in rapid dissolution of the active ingredient. The dosage form comprises the pharmaceutical binder methylcellulose in combination with low doses of a surfactant or a carbonate salt as disintegrants.

Abstract: An improved method for preparing tablets useful in diagnostic applications, utilizing trehalose as an excipient and stabilizer, is provided.

Abstract: The present invention is directed to a novel process for manufacturing tablets of N-halohydantoin compounds. In the process, at least one dry, particulate N-halohydantoin compound is blended with a dry, particulate alkali metal or alkaline earth salt to form a dry mixture, and the mixture is compacted into densified forms such as tablets. Dry particulate alkali metal or alkaline earth salts consist of a cation selected from among the group comprising lithium, sodium, potassium, magnesium and calcium and an anion selected from among the group comprising carbonate, bicarbonate, borate, silicate, phosphate, percarbonate, and perphosphate, to form a dry mixture and compressing the mixture.The invention is further directed to tablets produced by this process. The invention is also directed to mixtures comprising N-halohydantoin, one-half to three percent by weight alkali metal or alkaline earth salt, minor components and less than about five percent water.

Abstract: A process is described for the preparation of fat-soluble vitamin active beadlet compositions which exhibit superior stability when exposed to the feed pelleting process. The process includes forming an aqueous emulsion of a fat-soluble vitamin-active material, gelatin, and a sugar converting the emulsion to dry particulate form containing the non-aqueous constituents of the emulsion and heat treating the resulting product to form water insoluble beadlets.

Abstract: Storage stable, quick-disintegrating pressed shapes containing pharmaceutical active substances, which shapes consist substantially of a compressed mixture of(a) an effective amount of a pharmaceutical active substance in granular form, which is coated with a coating material comprising essentially a homogeneous mixture of a poly(H+meth)-acrylic acid-(methyl+ethyl) ester insoluble but dispersible in water and an ethyl cellulose insoluble but dispersible in water, the weight ratio of the acrylic acid ester to ethyl cellulose being 2.5:1 to 5:1;(b) talcum; and(c) colloidal silicon dioxide, and crosslinked polyvinylpolypyrrolidone as the disintegrating agent having a high disintegrating capacity and good binding properties.

Abstract: Polymers from ethylenically unsaturated monomers, cross-linked by a substituted or unsubstituted divinylazobenzene are useful as carriers or capsules for medicaments, which are degraded by the enzymes of the upper gastrointestinal tract or which must be transferred intact past the upper gastrointestinal tract, to deliver the medicament to the large intestine.Polymers containing monomeric units of the formulaH.sub.2 C.dbd.CH--C.sub.6 H.sub.4 --N.dbd.N--M,wherein M is the residue of an amino-containing medicament, are useful as carriers for therapeutic agents or as therapeutic agents per se.

Abstract: The invention relates to a process for manufacturing effervescent tablets consisting in the steps of careful humidifying of the acid+base mixture, pre-drying and final drying and granulating.It has been found that these operations can be performed in a single apparatus, either integrally in fluid bed, or with vacuum-drying.